FDA ta amince da maganin ƙwayar cuta don nuna rage yawan gut Fat by 15-18%
Ƙayyadewa
Egrifta (tesamorelin) wani abu ne mai ƙwayar cuta, wanda aka yi amfani da shi daga Cibiyar Abincin da Drug ta Amurka (FDA) a cikin watan Nuwamban 2010 domin maganin cutar lipodystrophy ta HIV .
Game da HIV-Associated Lipodystrophy
Rikicin lipodystro na kwayar cutar HIV yana da yanayin halin da wasu lokuta ke haifar da kullun jiki.
Yanayin da aka gabatar da nauyin fuska, ƙuƙwalwa, ko tsauri, yayin da yakan haifar da kullun a tara ciki, ƙirjinta, ko baya na wuyansa (wanda aka kira shi "buffalo hump" -like a bayyanar).
Rikicin lipodystrophy ta HIV ya sau da yawa an danganta shi da wasu nau'o'in magungunan rigakafi , ciki har da masu hana masu protease (PIs) da kuma wasu mawallafi masu juya baya (NRTIs) kamar Zerit (stavudine) da Videx (didanosine). Haka kuma yanayin zai iya haifar da kamuwa da kwayar cutar ta HIV, musamman ga marasa lafiya wadanda basu riga sun fara maganin cutar ba.
Yayin da ake gani da lipodystrophy sosai a cikin mutanen da ke dauke da kwayar cutar HIV tun lokacin da aka gabatar da sababbin magungunan kwayar cutar, to amma yana da matsala tun lokacin da yanayin ya kasance mai saurin gaske idan ya faru kuma koda an dakatar da magunguna.
Sanin Nuna Ƙwarewa da Hanyoyi
An nuna Egrifta a cikin marasa lafiya HIV dauke da kwayar cutar musamman don rage yawan ƙwayar visceral (watau mai da ke tarawa a cikin rami na ciki da kuma gabobin ciki).
Ba ya bayyana cewa yana da tasiri a kan lipoatrophy (asarar mai) na fuska, buttock ko wata gabar jiki, ko tarawa a kan ko dai cikin ƙirji ko baya na wuyansa.
Egrifta yana aiki ne ta hanyar motsawa gland shine ya saki hormone mai girma (HGH) , wanda aka san shi don inganta lipolysis (watau lalacewar lipids da triglycerides).
Nazarin sun nuna cewa farfadowa na Egrifta zai iya rage yawan mai ciki tsakanin 15% da 17% kamar yadda aka auna ta hanyar CT scan. Ƙarin gwaje-gwajen a shekarar 2014 sun nuna cewa Egrifta na iya rage yawan kitsen da ke kewaye da hanta ta kimanin kashi 18%.
Dosage da Gudanarwa
Matakan da aka ba da shawara mai girma na Egrift yana da 2mg injected subcutaneously (karkashin fata) sau ɗaya kowace rana. An bada shawarar cewa an yi wa Egrifta injected a cikin ciki a ƙarƙashin cibiya. Gudun magungunan shafewa yana taimakawa wajen rage ƙyallen da / ko hardening fata.
Egrifta an sake gina shi daga wata magungunan miyagun ƙwayoyi ta amfani da ruwa mai zurfi, wanda aka bayar da shi a cikin rami mai zurfi ( hoto ). Da zarar an sake sake ginawa, dole a yi amfani da miyagun ƙwayoyi nan da nan. Dole ne a adana Egrifta ba a cikin firiji tsakanin 36 da F da 46 o F (2 o C da 8 na C).
Egrifta ba a nuna shi ba don kula da asarar nauyi.
Duration da Kulawa na Far
Tun da ba a fahimci amfanin da ake amfani dadewa ba ko farfadowa na farfadowa, dole ne a yi ƙoƙari don saka idanu da maganin cutar ta hanyar duba CT ko kuma gwada ƙididdigar kunya. Idan mai haƙuri ba zai nuna rabuwa ta hanyar waɗannan hanyoyi ba, to sai a yi la'akari da dakatar da farfadowa.
Dole ne a yi amfani da tsawon lokacin farfadowa ta hanyar kai tsaye tare da likita na HIV / AIDs da aka samu a GHRH, ko tare da shawarwari tsakanin malamin HIV / AIDs da masanin kimiyyar likita.
Ya kamata a kula da ƙwayoyin glucose akai-akai a yayin da ake yin farfadowa tun lokacin da Egrifta na iya haifar da rashin haƙuri a glucose a wasu, sa marasa lafiya su kara yawan haɗari don ciwon sukari .
Hanyoyi na Common Side (faruwa a akalla 2% marasa lafiya)
- Haɗin gwiwa (arthralgia)
- Pain a cikin tsauraran matakai
- Raunin tsoka (myalgia)
- Rashin wutar lantarki, ƙumburi ko ciwo
- Tingling abin mamaki na fata (paresthesia)
- Ƙananan numbness na fata (hypoesthesia)
- Rash
- Flushing
- Itching (pruritis)
- Jiɗa
- Vomiting
Drug Interactions
Egrifta yana da hulɗa tare da kwayoyi masu biyo baya, ragewa / shayarwa da kanta da kuma miyagun kwayoyi:
- Cholesterol-ragewan magani: Zocor (simvastatin)
- HIV maganin rigakafin cutar HIV: Norvir (ritonavir)
Contraindications da tunani
Kada a ba Egrifta wa duk wanda ke fama da mummunan aiki , ko dai sabon bincikar lafiya ko sake dawowa yayin da HGH zai iya rinjayar ciwon ƙwayar ƙwayar ƙwayar ƙwayoyin jiki (tumo). Kula da hankali ga marasa lafiya da marasa ciwon magunguna ko wadanda ke da tarihin lalacewar rashin lafiya, ko la'akari da yiwuwar amfani da haɗari.
Egrifta yana nuna rashin amincewa a cikin marasa lafiya wadanda suka sami tiyata, tsinkayyar cutar kutsawa, hypopituitarism, rashawa, ko cirewa na glandon kwayoyin (hypophysectomy).
Egrifta ma an haramta wa mata masu juna biyu tare da kwayar cutar kwayar cutar HIV kamar yadda ya kamata a ci gaba da haifuwa a lokacin ciki da kuma ragewa ta hanyar hanyar GHRH zai iya cutar da tayin. Idan ciki ya faru, dakatar da farfadowar Egrifta.
Egrifta ba a nuna idan mai haƙuri yana da sanannun sanannun ga tesamorelin ko diuretic Osmitrol (mannitol).
Ya kamata a yi la'akari da hankali ga waɗanda ke fama da ciwon sukari kamar yadda Egrifta zai iya kara yawan ƙarfin insulin girma 1 (IGF-1) . Dole a yi la'akari da la'akari akai-akai don gano ci gaba ko kuma kara tsanantawa da cututtukan cututtuka na ciwon sukari (magunguna ko tsoma baki).
Sources:
Cibiyar Abinci da Druggun Amurka (FDA). "FDA ta amince da Egrifta don magance Lipodystrophy a cikin marasa lafiya na HIV." Silver Spring, Maryland; sanarwa da aka bayar ranar Nuwamba 10, 2010.
Stanley, T. Feldpausch, M .; Oh, J. et al. "Hanyoyin tesamorelin a kan kitsoyin lafiya a cikin marasa lafiya na kwayar cutar HIV: gwajin gwagwarmaya, wanda ake sarrafawa." Journal of the American Medical Association (JAMA). Yuli 23-30, 2014; 312 (4): 380-389.